MedTrace Logo

Minimal Optimal Dose of Sugammadex in Elective Surgery

NCT03515694 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-02-15

No results posted yet for this study

Summary

Time of appearance of TOF Ratio \>0,9 with different doses of Sugammadex

Conditions

  • Time of a TOF Ratio >0,9

Interventions

DRUG

Sugammadex Injection [Bridion]

Injection of 10mL of translucide solution

Sponsors & Collaborators

  • Erasme University Hospital

    lead OTHER

Principal Investigators

  • Wendy FERNANDEZ, Resident · Erasme University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-03
Primary Completion
2018-09-30
Completion
2018-09-30

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03515694 on ClinicalTrials.gov